
Exhibit 4.17 EXECUTION COPY SUPPLY AGREEMENT FERRER INTERNACIONAL, S.A. AND CUTANEA LIFE SCIENCES, INC. [***] = CERTAIN CONFIDENTIAL  INFORMATION  CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,  HAS   BEEN   {E1 OMITTED}  BECAUSE THE INFORMATION (I)  IS  NOT MATERIAL AND (II) WOULD  BE  COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUPPLY AGREEMENT This Supply Agreement (the "Agreement") is  {E2 made}  as of this ____  day  of  March ,  2018  (the "Effective  Date  "), by and between Cutanea Life Sciences, Inc., a corporation duly  {E3 organized}  and  existing  under the laws of the State of Delaware with its principal place of business at  1500  Liberty Ridge Drive, Suite 3000, Wayne, PA 19087 hereinafter  referred  to as "CUTANEA"), and Ferrer Internacional, S.A., a Spanish corporation with its principal place of business at Av. Diagonal, 549, 5t h floor, 08029 Barcelona (Spain) (hereinafter indistinctly  {E4 referred}  to as "Ferrer" and/or "Supplier"). CUTANEA and Ferrer  {E5 taken}  together hereinafter are  {E166 referred}  to as "PARTIES". WITNESSETH: WHEREAS, CUTANEA is  {E6 engaged}  in the distribution, promotion and sale of certain pharmaceutical, OTC and medical device products and in particular desires that Ferrer manufacture (directly and/or through a third party) and  {E7 supply}  CUTANEA with the "Products" (as  {E8 defined}  below); and WHEREAS, Ferrer and Medimetriks Pharmaceuticals, Inc. (hereinafter "Medimetriks")  {E9 entered}  into a License and Supply Agreement  dated   March 10, 2014 , as  {E10 amended}  , (hereinafter  {E11 referred}  as "LSA") pursuant to which among other things, Ferrer  {E12 granted}  Medimetriks exclusive commercialization and distribution rights to the Product (as  {E13 defined}  in the LSA) throughout the Territory (as  {E14 defined}  in the LSA); and WHEREAS, with Ferrer's consent, CUTANEA has  {E15 acquired}  and  {E16 assumed}  the rights, duties and obligations of Medimetriks under the LSA; and WHEREAS, Ferrer  {E17 desires}  to  {E18 manufacture}  (directly and/or through a third party) and  {E19 supply}  CUTANEA with such Products; NOW, THEREFORE, in consideration of the mutual covenants hereinafter  {E20 expressed}  , the Parties,  intending  to be legally  {E21 bound}  hereby,  {E22 agree}  as  follows  : 1. DEFINITIONS 1.1 Act "Act" means the Federal Food, Drug and Cosmetic Act, as amended, and regulations promulgated hereunder. 1.2 Business Day "Business Day" means any  day  other than a  Saturday ,  Sunday  or other  day  on which banks in Philadelphia, Pennsylvania and/ or Barcelona, Spain are permitted or required to close by any applicable law. [***] = CERTAIN CONFIDENTIAL  INFORMATION  CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,  HAS   BEEN   {E23 OMITTED}  BECAUSE THE INFORMATION (I)  IS  NOT MATERIAL AND (II) WOULD  BE  COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 1.3 Confidential Information "Confidential Information" means, other than information described in Section 9.1.2, all business and technical information, including third party information, in whatever form or manner presented, which is: (a) disclosed by or on behalf of a party (the "Disclosing Party") to the other party (the "Receiving Party") or learned or observed by the Receiving Party before or during the  term  of this Agreement; and (b) disclosed during any discussions and proceedings relating to any of the foregoing information, whether disclosed in oral, electronic, visual, written or any other form. "Confidential Information" shall  {E24 include}  all information of the Disclosing Party that the Disclosing Party would  {E25 consider}  confidential or proprietary under the circumstances. The fact that the Disclosing Party may have  {E26 marked}  or  {E27 identified}  as confidential or proprietary any specific information shall be indicative that such Disclosing Party  {E28 believes}  such information to be confidential or proprietary, but the failure to so  {E29 mark}  information shall not  {E30 determine}  that such information is or is not  {E31 considered}  confidential information by such Disclosing Party. 1.4 FDA "FDA" means the United States Food and Drug Administration, or any successor entity thereto. 1.5 Forecasted Needs "Forecasted Needs" means CUTANEA's estimate of Products (including in trade/sample form) to be ordered from Supplier for the upcoming rolling [***] period. 1.6 Governmental or Regulatory Authority "Governmental or Regulatory Authority" means governments, regulatory authorities, governmental departments, agencies, agents, commissions, bureaus, officials, courts, bodies, boards, tribunals or dispute settlement panels or other law, rule or regulation-making organizations or entities (a) having or purporting to have jurisdiction on behalf of any nation, territory or state or any other geographic or political subdivision of any of them, or (b) exercising, or entitled or purporting to exercise any administrative, executive, judicial, legislative, policy, regulatory or taxing authority or power. 1.7 Manufacture "Manufacture" means all the activities relating to production of the Products including packaging and shipment preparation, quality control and release of Products. All the references  {E32 contained}  in this Agreement  regarding  manufacturing activities shall be  {E33 deemed}   {E34 rendered}  by Supplier, even if  {E35 performed}  by its designee (whether in the form of a subcontractor, agent or otherwise). In consequence, all Manufacturing activities with respect to the Products to be  {E36 Manufactured}  hereunder by Supplier shall be  {E37 carried}  out by Supplier (or its designee) at the  {E38 notified}  facility and  {E39 utilizing}  equipment in the manner set forth in the Specifications, except to the extent that Supplier  {E40 receives}  CUTANEA's advance  {E41 written}  permission to  {E42 alter}  the location or  {E43 specified}  usage of the equipment that may be  {E44 required}  under the Specifications or the NDA, as applicable. 3 [***] = CERTAIN CONFIDENTIAL  INFORMATION  CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,  HAS   BEEN   {E45 OMITTED}  BECAUSE THE INFORMATION (I)  IS  NOT MATERIAL AND (II) WOULD  BE  COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 1.8 Product(s) "Product(s)" means product(s) as listed from time to time in Schedule A Manufactured by the Supplier (directly or through a third person) to meet the Specifications (as hereinafter defined); except as otherwise set forth on Schedule A, the Product will be ready for re-sale by CUTANEA to its customers in finished, final packaged form bearing CUTANEA's labels, it being understood that, after generic competition of the Product enters the market in the United States of America including Puerto Rico and the U.S. Virgin Islands, CUTANEA will be permitted to place orders for Product under a generic label. The  term  "Generic" shall be  {E46 interpreted}  as  {E47 defined}  under Section 1.17 of the LSA. 1.9 Specifications "Specifications" means, with respect to the Products, the critical quality standards that include test attributes, analytical procedures, and appropriate acceptance criteria and Manufacturing procedures for which such Product should conform to be considered acceptable for its intended use and conform to quality standards approved by Governmental and Regulatory Authorities and as provided in the NDA for the Products, and required for the Manufacture and supply of such Product(s). 1.10 Supply Price "Supply Price" means the price to be charged to CUTANEA from time to time by Supplier for Products Manufactured and supplied hereunder, as set forth in Schedule A. 2. PRODUCT MANUFACTURE AND SUPPLY 2.1 Manufacture and Purchase. Subject to the terms and conditions of this Agreement, Supplier  {E48 agrees}  that it will, on a non-exclusive basis (but exclusive for supply of the Product in the United States of America  including  Puerto Rico and the U.S. Virgin Islands), Manufacture (directly or through a designee) for and  {E49 provide}  and  {E50 supply}  to CUTANEA, and CUTANEA  {E51 agrees}  that it will  {E52 purchase}  exclusively from Supplier, all of its requirements of the Products as  follows  : Supplier shall  {E53 supply}  Products in accordance with the Specifications and in sufficient quantity to  {E54 meet}  CUTANEA's Forecasted Needs for the length of this Agreement. All deviations from the Specifications must be  {E55 approved}  by CUTANEA, in writing, prior to Supplier Manufacturing the Product. 2.2 Raw Materials and Components. As between Supplier and CUTANEA, Supplier shall be responsible for the supply of all raw materials and components necessary for the Manufacture of Products at no additional cost to CUTANEA. Supplier (or its designee) shall  {E56 order}  the initial components for each Product as soon as CUTANEA  {E57 provides}  Supplier (or its designee) with the relevant artwork for the Product. 4 [***] = CERTAIN CONFIDENTIAL  INFORMATION  CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,  HAS   BEEN   {E58 OMITTED}  BECAUSE THE INFORMATION (I)  IS  NOT MATERIAL AND (II) WOULD  BE  COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 2.3 Quality Tests and Checks. In order to  {E59 assure}  the conformity of the Products to the Specifications, the Supplier shall  {E60 deliver}  or  {E61 cause}  to be  {E62 delivered}  to CUTANEA, at the time of shipment, a certificate of analysis and compliance or other batch documentation upon reasonable request (such as, deviations, investigations, batch records) with respect to each batch of Product  {E63 supplied}  hereunder in the form  {E64 required}  by the Quality Agreement. 2.4 Forecasting and Other Obligations. 2.4.1 As soon as practicable  following  execution of this Agreement, but in any event within ten (10) Business Days, CUTANEA  {E65 agrees}  to  {E66 provide}  Supplier with a best estimate, non-binding (except for the first  six months ) forecast of its Forecasted Needs for Products ( including  in trade/sample form) for the upcoming rolling  18-month period  (the "Forecast"). Thereafter, CUTANEA will  {E67 update}  this  rolling  [***]  Forecast  quarterly. 2.4.2 With regards to the FDA Fees, CUTANEA shall  {E68 maintain}  the NDA for the Products and  {E69 pay}  , from time to time, all  {E70 required}  FDA filing and related Product fees. 2.4.3 CUTANEA shall  {E71 notify}  Supplier within one Business Day, after it  {E72 receives}  any materially adverse contact or communication from any Governmental or Regulatory Authority that  {E73 relates}  to any Product. Supplier shall  {E74 notify}  CUTANEA as soon as reasonably possible after it  {E75 receives}  any materially adverse contact or communication from any Governmental or Regulatory Authority that  {E76 relates}  to any Product and may reasonably be  {E77 expected}  to  {E78 affect}  patient safety. For matters that would not reasonably be  {E79 expected}  to  {E80 affect}  patient safety, Supplier shall  {E81 notify}  CUTANEA of such communications in its discretion. 2.4.4 CUTANEA shall  {E82 provide}  Supplier with copies of all communications  {E83 received}  from or  {E84 sent}  to any Governmental or Regulatory Authority with respect to any Product within three business  days  after receipt or  {E85 sending}  of the communication, as the case may be (subject to confidentiality and privilege restrictions, if any). CUTANEA shall  {E86 consult}  with Supplier  regarding  the response to any inquiry or observation from a Governmental or Regulatory Authority  relating  to a Product. CUTANEA shall  {E87 consider}  all reasonable requests and comments by Supplier with respect to all contacts and communications with a Governmental or Regulatory Authority. 2.5 Purchase Orders. 2.5.1 CUTANEA  {E88 agrees}  to  {E89 purchase}  from Supplier all Products  {E90 Manufactured}  for CUTANEA in accordance with valid CUTANEA Purchase Orders pursuant to the terms of this Agreement and  {E91 provided}  that such Products  {E92 meet}  the Specifications  {E93 approved}  by CUTANEA. 5 [***] = CERTAIN CONFIDENTIAL  INFORMATION  CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,  HAS   BEEN   {E94 OMITTED}  BECAUSE THE INFORMATION (I)  IS  NOT MATERIAL AND (II) WOULD  BE  COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 2.5.2 During the  term  of this Agreement, CUTANEA will  {E95 order}  Product(s) by  {E96 issuing}  firm Purchase Orders not less than [***] business  days  before the  {E97 requested}  delivery date(s) of such Product(s), and Supplier shall  {E98 provide}  approval of the Purchase Order by the Supplier within five (5) business  days   following  the Purchase Order reception, such approval  {E167 signifying}  Supplier's commitment to  {E99 deliver}  such Product(s) on the requested deliver date(s), it being  {E100 understood}  that Supplier must  {E101 accept}  a Purchase Order for delivery of Product not less than [***] business  days  before the  {E102 requested}  delivery date when  {E103 included}  in the first [***] of the Forecasted Needs. Each purchase order shall set forth the Product for which the purchase order is being  {E104 issued}  , the quantity being  {E105 ordered}  (in trade/sample form), the Supply Price for the Product(s) being  {E106 ordered}  and the  {E107 requested}  delivery date for the Product being  {E108 ordered}  , and the locations to which such quantities shall be  {E109 delivered}  . 2.5.3 Within ten (10) Business Days  following  this Agreement  {E110 becoming}  effective and thereafter on or before  the last day  of each calendar quarter, CUTANEA shall  {E111 provide}  Supplier with specific data as to its Forecasted Needs for such Product ( {E112 including}  in trade/sample form) for the  following  rolling [***]. Supplier will  {E113 use}  commercially reasonable efforts to  {E114 deliver}  Product to  CUTANEA  with minimum expiry dating  remaining  of [***]% of the  {E115 approved}  shelf-life. 2.5.4 CUTANEA's purchase orders shall  {E116 designate}  the  {E117 desired}  quantities of Products, delivery dates and destinations. Supplier shall  {E118 fill}  and  {E119 ship}  all orders of Products in accordance with CUTANEA's reasonable written instructions. CUTANEA'S purchase order may  {E120 specify}  up to three (3) shipping destinations per batch of Product but will be in full pallet quantities. Additional destinations can be  {E121 accommodated}  only upon CUTANEA payment of a shipping preparation fee to be  {E122 negotiated}  by Supplier and CUTANEA. 2.6 Acceptance / Rejection of Products. 2.6.1 All Products shall be  {E123 submitted}  to inspection and evaluation by or on behalf of CUTANEA to  {E124 determine}  whether or not  said  Products  {E125 meet}  the Specifications. CUTANEA will  {E126 provide}  in good faith  {E127 written}  acceptance of a batch of Product or  {E128 written}  notification of any deficiencies within two (2) Business Days after receipt of the Certificate of Analysis for the Product batch.  Written  acceptance of a batch of the applicable Product is  {E129 required}  as a condition to the delivery of Product to Cutanea's  {E130 designated}   shipping  agent in accordance with Section 3. If for any reason Supplier  does  not  {E131 receive}  any such notification within such two (2) Business Day period, Supplier will promptly  {E132 notify}  CUTANEA of such fact and CUTANEA will as soon as practicable and, in any event within another two (2) Business Days thereafter  {E133 provide}  such  {E134 written}  notice to Supplier and be responsible for any storage or similar charges that Supplier may  {E135 incur}  for not  {E136 delivering}  such Product. The lack of reception of such  {E137 written}  acceptance within the second two (2) Business Day period shall be  {E138 deemed}  as the batch is  {E139 accepted}  . If, once the Product is  {E140 delivered}  , CUTANEA  {E141 determines}  that there is any deficiency with respect to any Product, CUTANEA will  {E142 notify}  Ferrer of such claim within fifteen (15) Business Days of delivery of the Products. Each such notice of rejection to Supplier shall  {E143 specify}  in reasonable detail the ways in which the Product batch  {E144 failed}  to  {E145 meet}  Specifications. CUTANEA shall  {E146 grant}  to Supplier (or its designee) the right to  {E147 inspect}  or  {E148 test}   {E149 said}  Product batch and  {E150 dispute}  CUTANEA rejection  according  to the provisions  {E151 provided}  in this Section 2.6. In the event that Supplier  {E152 disagrees}  with CUTANEA's defective Product claim, the issue shall be  {E153 submitted}  to a mutually  {E154 agreed}  upon independent third party laboratory, whose decision shall be final and  binding  upon the Parties. The costs  {E155 arising}  from the laboratory's intervention and the costs of the  {E156 replaced}  Products ( including  return and destruction costs of the defective Products) shall be  {E157 borne}  by the Party whose results were  {E158 mistaken}  . As to any such Product batch which is determined to  {E159 fail}  the Specifications ("Rejected Product"), CUTANEA shall have no obligation to  {E160 pay}  for such Rejected Product and Supplier shall  {E161 replace}  such Rejected Product  as soon as possible  and no later than ninety (90)  days  thereafter. 6 [***] = CERTAIN CONFIDENTIAL  INFORMATION  CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,  HAS   BEEN   {E162 OMITTED}  BECAUSE THE INFORMATION (I)  IS  NOT MATERIAL AND (II) WOULD  BE  COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 2.6.2 In the event of a conflict between the test results of Supplier and the test results of CUTANEA with respect to any shipment of Product batch, within thirty (30)  days   following  receipt by Supplier of CUTANEA's notice of rejection, sample of such Product batch shall be  {E163 submitted}  by Supplier (and/or its nominee) to an independent laboratory  {E164 designated}  by Supplier (and/or its nominee) and reasonably acceptable to CUTANEA, which shall  {E165 perform}  an assessment and whose findings shall be conclusive.




